PGP and neoplasm: However, owing to the lack of tumor targeting and the fact that DTX is a P-glycoprotein (P-gp) substrate, systemic adverse effects and multidrug resistance (MDR) are commonly observed after a few courses of treatment (Gottesman et al., 2002), leading to premature termination of chemotherapy and consequently failure of anticancer treatment.